Company Overview

NUAgo Therapeutics is developing a new class of RNA-based therapeutics designed to address the limitations of current cancer treatments. Our approach is grounded in evolutionarily conserved biology and leverages the defining feature of the malignant state to selectively eliminate cancer while preserving normal tissue function.

From Malignant State to Therapeutic Action

sRNAs are selectively active in cancer cells because of the biological state that defines malignancy. The malignant state enables the biological condition necessary for sRNA activity in cancer cells. Cancer arises from mutations in normal cells, but mutations alone do not establish the functional capabilities required for malignancy. Cancer must gain additional functions and escape the constraints of normal cellular regulation to become malignant. Normal cellular function is maintained by high levels of microRNAs that regulate protein expression through RNA inhibition, locking in normal cellular function and differentiation. Malignant cells must lose this regulatory lock to escape these constraints. This biological distinction allows cancer cells to trigger DISE without affecting non-cancer cells.

NUAgo’s approach operates at a different level of cancer biology by targeting cellular survival networks. Cancer survival is maintained by interconnected networks of survival genes that support essential cellular functions. NUAgo’s single-construct short RNA (sRNA) therapeutics simultaneously reduce the expression of multiple survival genes, lowering cancer cell survival capacity and triggering a conserved cell death outcome.

Overcoming the Limits of Targeted Therapies

Most cancer drugs target individual mutations, components, or signaling pathways and can be effective in well-defined patient populations. These targeted therapies have transformed oncology for some patients. However, for most patients, these treatments fail. Failure is a structural problem inherent to target-based cancer therapies. Cancer survival is governed at the system level, not at the level of individual targets. These therapies focus on specific components while the cancer cell’s survival system remains intact. As long as that system continues to function, cancers adapt, persist, and resist therapy.

This biology-driven approach creates a repeatable therapeutic strategy that can be applied across multiple tumor types. NUAgo is translating this platform into a pipeline of cancer-specific programs, led by NU003, a therapeutic candidate designed for hepatocellular carcinoma.

Mission

Our mission is to advance biology-driven therapeutics that confront the limitations of current cancer treatments.

Vision

Our vision is to redefine disease treatment by regulating cellular networks at the RNA level.

Leadership

NUAgo is led by three PhD founders whose expertise spans scientific discovery, translational research, and biotechnology company development.

Two of the founders led the original scientific work underlying the company’s platform and continue to guide its scientific direction, ensuring that development decisions remain grounded in first-principles biology.

A third founder leads company strategy, operations, financing, and external partnerships. This leadership structure integrates discovery-level scientific authority with executive accountability, enabling disciplined development and credible engagement with partners.

NUAgo is supported by an advisory network and Board of Directors with experience across oncology research, translational medicine, and biotechnology company development.